Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Xing Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medici…. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Province, State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, National Natural Science Foundation of China.
Abstract (Originalsprache)
Discovery of small molecule inhibitors targeting Mcl-1 (Myeloid cell leukemia 1) confronts many challenges. Based on the fact that Mcl-1 is mainly localized in mitochondria, we propose a new strategy of targeting mitochondria to improve the binding efficiency of Mcl-1 inhibitors. We report the discovery of complex 9, the first mitochondrial targeting platinum-based inhibitor of Mcl-1, which selectively binds to Mcl-1 with high binding affinity. Complex 9 was mainly concentrated in the mitochondria of tumor cells which led to an enhanced antitumor efficacy. Complex 9 induced Bax/Bak-dependent apoptosis in LP-1 cells and synergized with ABT-199 to kill ABT-199 resistant cells in multiple cancer models. Complex 9 was effective and tolerable as a single agent or in combination with ABT-199 in mouse models. This research work demonstrated that developing mitochondria-targeting Mcl-1 inhibitors is a new potentially efficient strategy for tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovati…
- Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, The Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
- Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases, The Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
ORCID-Profile: Zhen-Feng Chen
Förderung
- Natural Science Foundation of Guangxi Province
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources
- National Natural Science Foundation of China
Zitieren
APA
Lu, X., Wu, M. F., Wu, J. L., Zhang, H. Q., Liang, H., & Chen, Z. F. (2023). Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00355
Vancouver
Lu X, Wu MF, Wu JL, Zhang HQ, Liang H, Chen ZF. Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00355
BibTeX
@article{Lu2023,
author = {Lu, Xing and Wu, Mei-Feng and Wu, Jiang-Lun and Zhang, Hai-Qun and Liang, Hong and Chen, Zhen-Feng},
title = {Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00355}
}
EUVIMED